Objective To study the clinical characteristics of systemic lupus erythematosus in male patients.Methods Clinieal data of 52 male patients with systemic lupus erythematosus were studied retrospectively.Results The age of onset of the male patients varied greatly and were predominant at the age of 10～20.Male patients were more susceptible to nephritis and more serious.The antibodies such as anti-ANA,anti-Sm and anti-ds-DNA were closely related to the severity of lupus nephritis(P＜0.05 of P＜0.01).Conclusion There are certain characteristics in male SLE,such as age of onset,such as age of onset,clinical manifestations and specific antibodies.

Oncolytic adenovirus-mediated E1A gene therapy may be a useful therapeutic approach for cancer treatment.In addition to direct lysis,viruses also mediate exogenous tumor suppressor genes inducing antitumor efficacy.Vectors need further investigation to improve the targeting and effectiveness in vivo.

Objective To observe the clinical curative effect of ginkgo dipyridolum injection for treatment of 96 patients with acute cerebral infarction. Methods 192 patients were divided into two groups, 96each: treated group and control group. Treated group patients was treated with ginkgo dipyridolum injection to intravenous drip, The control group patients was treated witht taushin injection. 2 weeks were 1 course. To observe and analyse the score、the clinical curative effect of dysneuria,the side effects after use the medicine. Results The clinical effective rate with ginkgo dipyridolum injection was 93.7%, the control group' s was 77.1%. The differences in the clinical effective rate between treated group and control group were significant (P < 0.05). Conclusions It is safe and has good effect to treat acute cerebral infarction with ginkgo dipyridolum injection. The clinical curative effect of ginkgo dipyridolum is better than tanshin injection's.

Diffuse large B-cell lymphoma (DLBCL) is the most common adult lymphoid malignancy accounting for 30 ％-40 ％ of all non-Hodgkin lymphoma (NHL).Young patients with high-risk DLBCL as a special group with poor clinical prognosis still can not receive standard treatment protocols in clinical practice at present.Conventional chemotherapy, combination of rituximab (R) to conventional CHOP chemotherapy, R-CHOP-like protocol, high-dose chemotherapy and autologous hematopoietic stem cell transplantation have not fully reversed the poor prognosis.This review focuses on the recent advances and future direction in the treatment of the young patients with high-risk DLBCL.

Adult ; Aged ; Biomarkers ; metabolism ; Case-Control Studies ; Hepatitis B, Chronic ; drug therapy ; Humans ; Middle Aged ; Treatment Outcome ; Vitamin D-Binding Protein ; metabolism ; Young Adult

Helicobacter pylori is closely related to many digestive system diseases,such as chronic gas-tritis,digestive ulcer,gastric mucosa associated lymphoid tissue lymphoma and gastric cancer,also leads to chil-dren with iron deficiency anemia,growth retardation,asthma,allergic diseases etc. So it is a key strategy to pre-vent and treat these diseases by eradicating Helicobacter pylori. Due to the increasing rates of antimicrobial resist-ance of clarithromycin and metronidazole,the eradication rate of standard triple therapy is 1ess than 80%in re-cent years. Especially in areas of high clarithromycin resistance and standard triple therapy have not been recom-mended as first-line therapy,it is necessary to investigate a new therapeutic strategy to improve the eradication rate of Helicobacter pylori. The new treatments for eradication of Helicobacter pylori in children is mainly based on sequential therapy,bismuth-based therapy,concomitant therapy and probiotics treatment. This article reviews the research progress of the new treatments in recent years.

Objective: To analyze the equity of benefit for inpatient services under the three basic medical insurance programs in China.Methods: Using the baseline survey data collected by China Family Panel Studies (CFPS) in 2010, and the two-part model was applied to explore whether the insured groups with different income levels had different aspects on inpatient rate and the compensation of hospitalization expenses in health insurance coverage.Results: There was no significant difference in the inpatient service utilization rate for different income groups, but the highest and second highest income groups reimburse more expenses than the lowest income group, that is 36.5% and 26.3%, respectively.Specifically, the income level and the compensation amount are not significantly correlated in the Urban Employer Medical Insurance (UEMI) program;the compensation amounts to be paid by urban residents are basically increasing with the increase of the income level;and there is a moderate discrepancy between the highest and the lowest income groups in the New Rural Cooperative Medical System (NCMS).Conclusion: The benefit equity is obviously fair in terms of inpatient service utilization rate, but the benefit degree increases for higher income groups, which shows that there are unfair inequalities related to the income at the level of reimbursement.In terms of program comparison, the benefit degree equity is higher for the UEMI program, followed by the URMI program and the NCMS program is the worst.Besides, the impatient rate and reimbursement amounts are significantly lower for NCMS program participants.The government should merge URMI and NCMS programs, actively promote the integration of basic medical insurance system by strengthening the construction of the medical assistance system and improving the system of catastrophic disease medical expenditure insurance in order to achieve better benefit equity.

Objective To study the management and prognosis of nongenital metastatic ovarian carcinoma. Methods Thirty-four patients with nongenital metastatic ovarian carcinoma who were admitted in to Zhongnan Hospital of Wuhan University between 1998 and 2004 were analyzed retrospectively. Results The median survival time of group A (optimal cytoreductive surgery), group B (optimal cytoreductive surgery+chemotherapy), group C (sub-optimal cytoreductive surgery) and group D (sub-optimal cytoreductive surgery+chemotherapy ) was 5.0,10.0,4.0 and 6.5 months, respectively. The difference was significant between groups A and B, B and C, as well as between group C and D(P

It is possible for bone marrow cells,peripheral blood cells,myocardial cells,muscle cells and embryonic stem cells differentiating into smooth muscle progenitor cells(SPCs),which can express special marks of myosin heavy chain.SPCs remained quiescent,until mobilized in response to injury or disease.With various growth factors,cytokines,SPCs are mobilized following physiological stress and subsequently home to site of vascular damage,where they contribute to the remodeling process.Recently,various studies have found that SPCs from different sources contributed to the remodeling process of vessels and development in atherosclerosis.It is generally accepted that SPCs contribute to pathological changes,leads to restenosis.But several recent papers reported findings that injection of SPCs increased collagen and SMC content and reduced macrophage content,consistent with a more stable plaque.SPCs may secrete cytokines and growth factors both locally and systemically that enhance plaque stability.It remains to be determined whether smooth progenitor cells,which are less well studied than their endothelial counterparts,can likewise be manipulated to achieve therapeutic genes benefit.This review has elucidated the origin and distribution of SPCs,mobilization and recruitment,and their roles in cardiac vascular diseases.